A detailed history of Greenleaf Trust transactions in Moderna, Inc. stock. As of the latest transaction made, Greenleaf Trust holds 3,505 shares of MRNA stock, worth $138,762. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,505
Previous 5,399 35.08%
Holding current value
$138,762
Previous $641,000 63.49%
% of portfolio
0.0%
Previous 0.01%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 22, 2024

SELL
$63.64 - $125.14 $120,534 - $237,015
-1,894 Reduced 35.08%
3,505 $234,000
Q2 2024

Jul 22, 2024

BUY
$101.21 - $166.61 $217,196 - $357,545
2,146 Added 65.97%
5,399 $641,000
Q1 2024

Apr 29, 2024

BUY
$85.37 - $115.44 $81,357 - $110,014
953 Added 41.43%
3,253 $346,000
Q4 2023

Jan 31, 2024

SELL
$69.51 - $104.43 $33,712 - $50,648
-485 Reduced 17.41%
2,300 $228,000
Q3 2023

Nov 09, 2023

SELL
$96.41 - $126.61 $29,597 - $38,869
-307 Reduced 9.93%
2,785 $287,000
Q2 2023

Aug 09, 2023

SELL
$118.5 - $160.53 $50,362 - $68,225
-425 Reduced 12.08%
3,092 $375,000
Q1 2023

May 11, 2023

SELL
$135.66 - $197.02 $209,866 - $304,789
-1,547 Reduced 30.55%
3,517 $540,000
Q4 2022

Jan 25, 2023

BUY
$118.38 - $210.04 $266,473 - $472,800
2,251 Added 80.02%
5,064 $910,000
Q3 2022

Nov 10, 2022

SELL
$118.07 - $194.18 $25,621 - $42,137
-217 Reduced 7.16%
2,813 $333,000
Q2 2022

Aug 12, 2022

BUY
$117.13 - $176.59 $13,001 - $19,601
111 Added 3.8%
3,030 $433,000
Q1 2022

Apr 27, 2022

BUY
$126.46 - $235.05 $24,280 - $45,129
192 Added 7.04%
2,919 $503,000
Q4 2021

Feb 11, 2022

SELL
$225.82 - $368.51 $167,332 - $273,065
-741 Reduced 21.37%
2,727 $693,000
Q3 2021

Nov 12, 2021

BUY
$221.9 - $484.47 $769,549 - $1.68 Million
3,468 New
3,468 $1.34 Million

Others Institutions Holding MRNA

About Moderna, Inc.


  • Ticker MRNA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 391,200,000
  • Market Cap $15.5B
  • Description
  • Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, resp...
More about MRNA
Track This Portfolio

Track Greenleaf Trust Portfolio

Follow Greenleaf Trust and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Greenleaf Trust, based on Form 13F filings with the SEC.

News

Stay updated on Greenleaf Trust with notifications on news.